Brokers expect SQZ Biotechnologies (NYSE:SQZ – Get Rating) to report earnings per share of ($0.71) for the current quarter, reports Zacks. Two analysts have made estimates for SQZ Biotechnologies’ earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.70). SQZ Biotechnologies reported earnings per share of ($0.59) for the same quarter last year, indicating a negative year-over-year growth rate of 20.3%. The company is expected to release its next earnings report on Monday, January 1st.
On average, analysts expect SQZ Biotechnologies to report full year earnings per share for the current fiscal year of ($2.68) with EPS estimates ranging from ($3.50) to ($1.83). For the next fiscal year, analysts are forecasting that the company will report earnings per share of ($3.30) with EPS estimates ranging from ($5.13) to ($2.22). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts covering SQZ Biotechnologies.
SQZ Biotechnologies (NYSE:SQZ – Get Rating) last announced its earnings results on Wednesday, March 16th. The company reported earnings per share (EPS) of $0.41 for the quarter, beating analyst consensus estimates of $0.67 by $0.26. The company had revenue of $12.35 million for the quarter, compared to analyst estimates of $7.99 million. SQZ Biotechnologies had a negative net margin of 253.68% and a negative return on equity of 47.47%.
Shares of NYSE:SQZ fell $0.04 during Friday trading to hit $3.69. 1,479,804 shares of the company traded compared to an average volume of 125,652. The company has a 50-day simple moving average of $4.47 and a 200-day simple moving average of $8.28. The company has a market cap of $103.87 million, a P/E of -1.49 and a beta of 4.41. SQZ Biotechnologies has a 1 year low of $2.73 and a 1 year high of $16.17.
Several institutional investors have recently added to or reduced their stakes in the company. Citigroup Inc. increased its stake in SQZ Biotechnologies by 139.6% in the third quarter. Citigroup Inc. now owns 2,595 shares of the company’s stock valued at $37,000, having purchased an additional 1,512 shares during the period. The Royal Bank of Canada increased its stake in SQZ Biotechnologies by 96.2% in the third quarter. The Royal Bank of Canada now owns 3,059 shares of the company, valued at $44,000, having purchased an additional 1,500 shares during this period. Bangor Savings Bank bought a new $99,000 position in SQZ Biotechnologies during the fourth quarter. UBS Group AG increased its stake in SQZ Biotechnologies by 85.8% in the third quarter. UBS Group AG now owns 7,000 shares of the company, valued at $101,000, having purchased an additional 3,233 shares during the period. Finally, Metropolitan Life Insurance Co NY bought a new position in SQZ Biotechnologies valued at $104,000 during the third quarter. Institutional investors and hedge funds own 49.07% of the company’s shares.
SQZ Biotechnologies company profile (get rating)
SQZ Biotechnologies Company, a clinical-stage biotechnology company, is developing cell therapies for patients suffering from cancer, autoimmune diseases, infectious diseases and other serious diseases. Its lead product candidate is SQZ-PBMC-HPV from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical , head and neck, anal, penile, vulva and vaginal cancer.
Get a Free Copy of the Zacks Research Report on SQZ Biotechnologies (SQZ)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Receive News & Reviews for SQZ Biotechnologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SQZ Biotechnologies and related companies with MarketBeat.com’s FREE daily email newsletter.